"As we have seen with the recent clinical trial results, CAR T cells have shown potential in treating solid tumors, an area previously less responsive to this technology."
"The recent developments indicate a significant advancement in CAR T cell therapy, with 35% of participants in the trial responding positively to the treatment."
A recent clinical trial in China exploring CAR T cells, known for treating blood cancers, demonstrated potential in combating solid tumors. The trial reported a 35% response rate among participants receiving satri-cel, a new CAR T treatment, which showed a 31% reduced mortality risk compared to control. While these results are promising, they come with notable side effects. Additionally, there’s optimism as some patients have reported long-term remission, indicating CAR T therapy's evolving efficacy against cancers not previously addressed effectively.
Read at InsideHook
Unable to calculate read time
Collection
[
|
...
]